Drug Type Small molecule drug |
Synonyms 2,5-Dihydroxybenzenesulfonic-acid-monopotassium-salt, Potassium dobesilate, Potassium-2,5-dihydroxybenzenesulfonate |
Target |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC6H6KO5S |
InChIKeyWHUCYROEYGJKNI-UHFFFAOYSA-N |
CAS Registry21799-87-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Actinic Keratosis | Phase 2 | US | 06 Jun 2017 | |
Plaque psoriasis | Phase 2 | DO | 21 Dec 2016 | |
Psoriasis | Phase 2 | US | 01 Aug 2013 |